Active Stocks
Thu Apr 18 2024 15:59:07
  1. Tata Steel share price
  2. 160.00 -0.03%
  1. Power Grid Corporation Of India share price
  2. 280.20 2.13%
  1. NTPC share price
  2. 351.40 -2.19%
  1. Infosys share price
  2. 1,420.55 0.41%
  1. Wipro share price
  2. 444.30 -0.96%
Business News/ Industry / Manufacturing/  Zydus Cadila collaborates with German researcher Pieris
BackBack

Zydus Cadila collaborates with German researcher Pieris

Firms have signed a research alliance to develop and sell multiple anticalin protein therapeutics

Cadila Health, also known as Zydus Cadila, said on Wednesday that the collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertize in biologics development, regulatory affairs and biologics manufacturing. Photo: BloombergPremium
Cadila Health, also known as Zydus Cadila, said on Wednesday that the collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertize in biologics development, regulatory affairs and biologics manufacturing. Photo: Bloomberg

Mumbai: Cadila Healthcare Ltd and German biopharmaceutical company Pieris AG have signed a research alliance to develop and sell multiple anticalin protein therapeutics, a new class of drugs that can be used for the treatment of a variety of disorders.

Cadila Health, also known as Zydus Cadila, said on Wednesday that the collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertize in biologics development, regulatory affairs and biologics manufacturing.

Zydus will have the exclusive marketing rights in India and several other emerging markets for the product, while Pieris retains exclusive marketing rights in key developed markets including the US and Europe.

“Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus’ ongoing transformation into an innovation-led global healthcare provider; we are pleased to add anticalins to our novel biological pipeline," Pankaj R. Patel, chairman and managing director of Zydus group, said in a statement.

“This collaboration will allow Pieris to unlock value on a global scale in a cost-effective manner, significantly expanding the number of propriety anticalin programmes we can advance into clinical trials." said Stephen Yoder, chief executive officer of Pieris.

Pieris has a similar agreement with Japan’s Daiichi Sankyo Co. Ltd, French drugmaker Sanofi SA, and US drugmaker Allergan Inc. on anticalin. Through this unique collaborative model, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories at the appropriate time, the release stated. The companies will share licensing revenue on mutually agreed terms.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 16 Oct 2013, 11:56 PM IST
Next Story footLogo
Recommended For You
Manufacturing Stocks
₹608.751.26%
ITC
₹425.95-1.64%
₹2,934.45-0.21%
₹1,536.95-0.86%
₹160.05-0.03%
Switch to the Mint app for fast and personalized news - Get App